Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1473-3099(19)30277-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation.
Haematologica
November 2019
Department of Haematology, Henri Mondor Hospital, Assistance Publique-Hopitaux de Paris, Université Paris-Est Créteil, Créteil, France.
Article Synopsis
- There are two types of a virus called human herpesvirus 6 (HHV-6), and one of them, HHV-6B, can cause serious brain problems after people get a stem cell transplant.
- Ten years ago, guidelines were made to help doctors treat HHV-6 infections, but there haven’t been updated guidelines since then.
- New guidelines were created in 2017 to help doctors better diagnose, prevent, and treat HHV-6 diseases in patients who have had a stem cell transplant or have blood cancers.
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Lancet Infect Dis
August 2019
Division of Infection and Immunity, University College London, London, UK.
Cytomegalovirus is one of the most important infections to occur after allogeneic haematopoietic stem cell transplantation (HSCT), and an increasing number of reports indicate that cytomegalovirus is also a potentially important pathogen in patients treated with recently introduced drugs for hematological malignancies. Expert recommendations have been produced by the 2017 European Conference on Infections in Leukaemia (ECIL 7) after a review of the literature on the diagnosis and management of cytomegalovirus in patients after HSCT and in patients receiving other types of therapy for haematological malignancies. These recommendations cover diagnosis, preventive strategies such as prophylaxis and pre-emptive therapy, and management of cytomegalovirus disease.
View Article and Find Full Text PDFPossible pitfalls of the 2017 ECIL guidelines.
Lancet Infect Dis
June 2019
Infectious Diseases Unit, Scientific Institute for Research, Hospitalization, and Health Care, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
Int J Antimicrob Agents
June 2019
Service de réanimation et maladies infectieuses, CH Tourcoing, 59208 Tourcoing, France.
Objectives: Antibiotics for febrile neutropenia (FN) in acute myeloid leukaemia (AML) patients undergoing intensive chemotherapy are usually maintained until neutropenia resolution, because of the risk of uncontrolled sepsis in this vulnerable population. This leads to unnecessarily prolonged antimicrobial therapy.
Methods: Based on ECIL-4 recommendations, we modified our management strategy and discontinued antibiotics after a pre-established duration in patients treated for a first episode of FN between August 2014 and October 2017.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!